What is the market's earnings forecast for Pulmonx next quarter?

What is Pulmonx's latest dividend and current dividend yield?

What factors drove the changes in Pulmonx's revenue and profit?

What does Pulmonx do and what are its main business segments?

What were the key takeaways from Pulmonx’s earnings call?

Did Pulmonx beat or miss consensus estimates last quarter?

What guidance did Pulmonx's management provide for the next earnings period?

What were the key takeaways from Pulmonx's earnings call?

- **Leadership Reboot**: CEO and CFO return to address execution gaps, focusing on profitable growth and cost control.
- **Q3 Growth**: International revenue up 15%, gross margin 75%, with updated 2025 guidance of $89-90M revenue.
- **Execution Priority**: Streamline patient workflows, replicate top-performing territories, and reduce underperforming US centers.
- **Financial Discipline**: 73% gross margin target, $1M non-cash expenses, and $89M revenue guidance.
- **Cash Management**: Extend runway via spending realignment, no external financing, and focus on high ROI initiatives.

**Core Details - Detail Page**

**CEO Summary Section**
- **Leadership Transition**: Glenn French and Derrick Sung returned to their roles as CEO and COO/CFO, respectively, to address execution challenges and drive profitable growth.
- **Foundation Strength**: Pulmonx’s Zephyr valves remain the standard of care for severe emphysema, with strong clinical evidence and reimbursement in key markets.
- **Challenges Acknowledged**: Slowed US sales growth, underperforming territories, and elusive operating leverage. Focus on aligning spending with growth expectations and improving execution.
- **Strategy**: Narrow investments to high-impact areas, prioritize profitable growth, and extend cash runway through disciplined capital allocation.

**CFO Financial Commentary**
- **Q3 2025 Results**: Total revenue $21.5M (+5% YoY), US revenue $14M (+1%), international $7.5M (+15%). Gross margin 75% (vs. 74% YoY).
- **Expenses**: Operating expenses $30.4M (+4%), R&D $4.8M (+29%), SG&A $25.6M (+1%). Net loss $14M, adjusted EBITDA loss $8.2M.
- **Guidance Update**: Full-year 2025 revenue $89-90M, gross margin ~73%, operating expenses $125-126M.
- **Cash Position**: $76.5M in cash, $25M cash utilization YTD. Focus on reducing burn and extending runway.

**Q&A Key Highlights**
- **Strategic Pathways**: No immediate plans for asset sales/partnerships; focus on optimizing existing assets and reallocating resources.
- **US Growth Slowdown**: Underperforming territories offset strong international growth; plans to replicate high-performing territories.
- **Patient Referral Process**: Streamlining workflows to reduce delays; efficient processing in top accounts drives volume.
- **Cash Runway Extension**: No external financing; reallocating to high ROI initiatives, reducing non-core spending.
- **Execution Focus**: Prioritize profitable growth, same-store sales, and efficient patient processing.


Pulmonx Corporation (LUNG) Q3 2025 Earnings Call Transcript

- **Revenue guidance revised down**: Full year 2025 outlook adjusted to $90-92M (prev. $96-98M) due to slower U.S. initiative ramp.
- **U.S. growth challenges**: Capacity constraints at IP centers and diverted focus to lung cancer screening delaying procedure volume recovery.
- **International strength**: Europe/Asia direct markets drive 32% YoY growth, offsetting China distributor moderation.
- **Strategic momentum**: LungTrax Detect adoption (5 patients flagged in 30 days) and TAS roles (+19% workups) signal long-term growth potential.
- **Financial discipline**: Operating expenses reduced to $128-130M, preserving cash while funding key initiatives.


**【CEO Opening Remarks】**
- Q2 2025 revenue: $23.9 million (+15% YoY). International revenue ($9.1M, +32% YoY) exceeded expectations, while U.S. revenue ($14.7M, +6% YoY) lagged due to slower procedure volume growth.
- U.S. challenges: Decline in StratX scans, capacity constraints at IP centers, and diversion of focus to robotic bronchoscopy and lung cancer screening.
- Strategic initiatives: Direct-to-patient outreach (70,000+ engagements), LungTrax Detect AI tool, and therapy awareness specialists (TAS) driving 19% increase in patient workups.
- Revised 2025 guidance: $90-92M (prev. $96-98M), reflecting delayed U.S. initiative ramp-up but maintaining confidence in long-term growth.

**【CFO Financial Commentary】**
- Gross margin: 72% (vs. 74% YoY), impacted by international distributor mix.
- Operating expenses: $32M (+3% YoY), with R&D up 36% YoY (clinical trial investments).
- Net loss: $15.2M (-0.38 EPS), consistent with prior year.
- Cash position: $84.2M, with $17.3M first-half cash utilization.
- Revised 2025 outlook: Revenue $90-92M, operating expenses $128-130M, gross margin ~74%.

**【Q&A Highlights】**
- **Q3/Q4 Expectations**: U.S. revenue to account for ~67% of total in H2, with Q3 flat YoY and Q4 growth dependent on initiative ramp.
- **StratX Trends**: June/July scans at record levels, driven by LungTrax Detect adoption (e.g., 5 patients flagged in 30 days at one hospital).
- **Competitive Landscape**: No direct competition; focus on building lung health ecosystems alongside lung cancer screening programs.
- **China Impact**: First-half distributor revenue will moderate in H2, but direct international markets remain strong.


Pulmonx Corporation (LUNG) Q2 2025 Earnings Call Transcript

- **Revenue beat expectations**: Q1 2025 revenue up 20% YoY ($22.5M), driven by 39% international growth (China, Japan) and 11% U.S. growth.
- **Strategic momentum**: LungTraX Detect pilot sites seeing 15% emphysema detection rate, 10 new U.S. accounts added.
- **Legal clarity**: DOJ resolved False Claims Act case, reducing execution risk.
- **China risk mitigation**: Distributor pre-buy offset potential trade policy disruptions.
- **2H25 growth catalysts**: Therapy awareness specialists, LungTraX Detect adoption, and 2026 AeriSeal launch.

**【CEO Summary Section】**
- Q1 2025 worldwide revenue reached $22.5 million, up 20% YoY, driven by 39% international growth (China and select markets) and 11% U.S. growth.
- Acquired-test-treat strategy progress: 
  - 40+ peer-to-peer education events for pulmonologists, 37,000+ clinicians engaged via Medscape CME.
  - LungTraX Detect system now in pilot at ~dozens of hospitals, detecting 15% emphysema patients in CT scans.
  - 10 new U.S. accounts added, total active accounts 285.
- International expansion: Japan post-market surveillance study with 500+ physician engagements; AeriSeal CONVERT II trial enrollment ongoing.
- DOJ CID resolved: DOJ declined to intervene in False Claims Act case, reducing legal risk.

**【CFO Financial Commentary】**
- Q1 2025 GAAP net loss: $14.4 million (-$0.36/share) vs. $13.7 million (-$0.36/share) prior year.
- Key metrics: 
  - Gross margin: 73% (down 200bps vs. prior year due to international mix).
  - Operating expenses: $30.9 million (+8% YoY), driven by +$1.7 million in SG&A (DTP programs, therapy awareness specialists).
  - R&D: $4.8 million (+$0.6 million YoY) for clinical trial expansion.
- Cash position: $88.7 million (down $12.8 million QoQ due to annual bonuses).
- 2025 guidance reaffirmed: $96-98 million revenue, 74% gross margin, $133-135 million opex.

**【Q&A Key Themes】**
- **China stocking**: Distributor bought ~1Q worth of inventory ahead of macro uncertainty, expect continued Q2 orders.
- **U.S. growth slowdown**: 4Q24/Q125 tough comps, but LungTraX Detect adoption and therapy awareness specialists (7 hired) expected to accelerate 2H25 growth.
- **Tariffs impact**: Minimal direct impact as products manufactured in U.S., but monitoring global trade policy.
- **R&D spending**: Clinical trial costs will rise with enrollment, but expect leverage post-2026 AeriSeal launch.
- **Cash flow breakeven**: Confident with current liquidity and operating leverage trends.

Pulmonx (LUNG)-30 Apr 25-2025 Q1 Earnings call transcript

- **Revenue Surge**: Q4 2024 revenue up 23% YoY to $23.8M, full-year 2024 at $83.8M (+22% YoY). U.S. sales +16%, international +42%.
- **LungTraX Breakthrough**: AI-driven platform identifies 10-15% of chest CTs with emphysema, 71% of patients not tested for pulmonary function. Full rollout Q2 2025.
- **Clinical Momentum**: AeriSeal CONVERT Trial success (77.6% ventilation), Japan commercialization in 2026, U.S. launch 2027.
- **2025 Outlook**: Guided $96-98M revenue (+17% midpoint), targeting 20%+ long-term growth via acquire-test-treat strategy.
- **Financial Strength**: $101.5M cash, 74% gross margin, operating leverage improving (adjusted EBITDA -20% YoY).

**【CEO Summary Section】**
- **Revenue Growth**: Q4 2024 revenue of $23.8M (+23% YoY), full-year 2024 revenue of $83.8M (+22% YoY). U.S. sales grew 16% YoY to $15.9M, international sales surged 42% YoY to $7.9M.
- **Strategic Initiatives**: Launched LungTraX platform (Detect & Connect) to streamline patient workflows, expanded physician education programs, and added 52 new U.S. accounts (total 283 active accounts).
- **Clinical Progress**: AeriSeal CONVERT Trial achieved 77.6% collateral ventilation success, 89% low lung volume reduction.日本 post-market surveillance study progressing for 2026 commercialization.
- **Long-Term Vision**: Target 20%+ annual growth driven by acquire-test-treat strategy, $12B addressable market, and global expansion (Europe, China, Japan).

**【CFO Financial Commentary】**
- **Q4 2024 Results**: GAAP net loss of $13.2M (-2% YoY), adjusted EBITDA loss of $7.5M (-10% YoY). Full-year 2024 cash balance of $101.5M, down $30M YoY due to strategic investments.
- **2025 Guidance**: Revenue $96-98M (+17% midpoint), gross margin ~74%, operating expenses $133-135M (+12% YoY). Expect U.S. acceleration in H2 2025, international growth in H1 2025.
- **Financial Health**: Demonstrated operating leverage (adjusted EBITDA improved 20% YoY), cost optimization initiatives reducing OpEx burn rate by 16% YoY.

**【Q&A Key Highlights】**
- **LungTraX Impact**: Early pilot results show 10-15% of chest CTs identify radiographic emphysema, with 71% of patients not having pulmonary function tests. Full rollout expected Q2 2025.
- **International Growth**: China distributor orders drove 42% YoY international growth. Europe adopting U.S. sales strategies, Japan post-market study on track for 2026 launch.
- **Gross Margin Trends**: 74% for 2025, trending higher in H2 due to scale, geographic mix, and cost optimization. Long-term margin expansion via manufacturing leverage.
- **2025 Execution**: 17% YoY growth guided vs. 20%+ long-term target. H1 2025 focused on scaling pilots, H2 2025 acceleration from LungTraX, marketing, and clinical trials.


LUNG

LUNG fundamentals

Earnings Call

You can ask Aime